North America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)
The North America monoclonal antibodies market is expected to reach US$ 1,20,713.2 million by 2028 from US$ 54,629.4 million in 2021. The market is estimated to grow at a CAGR of 12.0% from 2021–2028.
According to the International AIDS Vaccine Initiative (IAVI) report, the development of mABs is one of the fastest-growing segments of biomedical research. For records, more than 50 mABs were licensed in the last six years, and in 2019, seven of the ten best-selling novel drugs for cancer and autoimmune diseases were mABs. Further, with the growing number of non-communicable and infectious diseases, for which mABs are or might prove effective treatment, there is certainly an accelerating demand for such products. For example, mABs sales are predominant in the US. As the percentage of mABs in the development pipeline increases, more and more mABs will enter the market, and the disparity in access between high-income countries and the rest of the world will worsen. Furthermore, a few combinations of mABs are also being developed to address many diseases, including chronic infections and cancer. On the other hand, several counties are taking strong initiatives to shorten the regulatory process for mABs effective for treating chronic diseases. For records, in early 2019, the CFDA approved three mABs from domestic developers and ten mABs from multinational pharmaceutical companies. Such factors are stimulating the uptake of mABs, aiding the market significantly.Favorable government regulations in North America regional market authorizes monoclonal antibodies during the onset of the pandemic. For instance, in December 2021, The US Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) intended for pre-exposure prophylaxis of COVID-19 for certain adults and pediatric individuals. As monoclonal antibodies are laboratory manufactured proteins involved in mimicking the immune system's ability to fight off harmful pathogens such as viruses. Therefore, "Tixagevimab" and "cilgavimab" are long-acting monoclonal antibodies particularly directed for spike protein of SARS-CoV-2. Apart from that, favorable funding for development of biologics further enhanced the market growth for monoclonal antibodies during the onset of pandemic in North America regional market. For example, the US International Development Finance Corporation (DFC) announced furnishing of US$50 million to Biological E Limited for increasing COVID-19 vaccine manufacturing capacity. Also, favorable policy relating to product approvals for biologics by the FDA positively impacts the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The North America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
North America Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
North America Monoclonal Antibodies Market Segmentation
By Source
- Human
- Humanized
- Chimeric
- Murine
By Production Method
- In-Vitro
- In-Vivo
By Indication
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Inflammatory Diseases
- Microbial Diseases
- Others
By Application
- Therapeutic Applications
- Diagnostic Applications
- Research Applications
By End-User
- Hospitals
- Research Institutes
- Others
By Country
- North America
- US
- Canada
- Mexico
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Monoclonal Antibodies (mAbs) Market – By Source
1.3.2 North America Monoclonal Antibodies (mAbs) Market – By Production Method
1.3.3 North America Monoclonal Antibodies (mAbs) Market – By Indication
1.3.4 North America Monoclonal Antibodies (mAbs) Market – By Application
1.3.5 North America Monoclonal Antibodies (mAbs) Market – By End-User
1.3.6 North America Monoclonal Antibodies (mAbs) Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Monoclonal Antibodies (mAbs) Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. Monoclonal Antibodies (mAbs) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases
5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak
5.2 Market Restraints
5.2.1 Low Awareness, Accessibility, and High Cost
5.3 Market Opportunities
5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity
5.4 Future Trends
5.4.1 Strategic Research Collaborations
5.5 Impact Analysis
6. Monoclonal Antibodies (mAbs) Market– North America Analysis
6.1 North America Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis
7. North America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source
7.1 Overview
7.2 North America Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)
7.3 Murine
7.3.1 Overview
7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Chimeric
7.4.1 Overview
7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Humanized
7.5.1 Overview
7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Human
7.6.1 Overview
7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method
8.1 Overview
8.2 North America Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
8.3 In-Vivo
8.3.1 Overview
8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
8.4 In-Vitro
8.4.1 Overview
8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication
9.1 Overview
9.2 North America Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
9.3 Cancer
9.3.1 Overview
9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.5 Inflammatory Diseases
9.5.1 Overview
9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.6 Infectious Diseases
9.6.1 Overview
9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.7 Microbial Diseases
9.7.1 Overview
9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application
10.1 Overview
10.2 North America Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
10.3 Diagnostic Applications
10.3.1 Overview
10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.4 Therapeutic Applications
10.4.1 Overview
10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.5 Research Applications
10.5.1 Overview
10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User
11.1 Overview
11.2 North America Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
11.3 Hospitals
11.3.1 Overview
11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.4 Research Institutes
11.4.1 Overview
11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis
12.1 North America: Monoclonal Antibodies (mAbs) Market
12.1.1 Overview
12.1.2 North America: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.3 North America: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)
12.1.4 North America: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)
12.1.5 North America: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)
12.1.6 North America: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)
12.1.7 North America: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)
12.1.8 North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
12.1.8.1 US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.1 Overview
12.1.8.1.2 US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.3 US: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)
12.1.8.1.4 US: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)
12.1.8.1.5 US: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)
12.1.8.1.6 US: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)
12.1.8.1.7 US: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)
12.1.8.2 Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.1 Overview
12.1.8.2.2 Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.3 Canada: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)
12.1.8.2.4 Canada: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)
12.1.8.2.5 Canada: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)
12.1.8.2.6 Canada: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)
12.1.8.2.7 Canada: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)
12.1.8.3 Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.1 Overview
12.1.8.3.2 Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.3 Mexico: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)
12.1.8.3.4 Mexico: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)
12.1.8.3.5 Mexico: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)
12.1.8.3.6 Mexico: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)
12.1.8.3.7 Mexico: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)
13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
14. Monoclonal Antibodies (mAbs) Market–Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market, (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 Novartis AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 GlaxoSmithKline plc.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Amgen Inc.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 DAIICHI SANKYO COMPANY LIMITED
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 F. HOFFMANN-LA ROCHE LTD.
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 AstraZeneca
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Eli Lilly and Company.
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Bayer AG
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Bristol-Myers Squibb Company
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (USD Million)
Table 3. North America Monoclonal Antibodies (mAbs) Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Monoclonal Antibodies (mAbs) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Monoclonal Antibodies (mAbs) Market, by End-User– Revenue and Forecast to 2028 (US$ Million)
Table 6. US Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 7. US Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)
Table 8. US Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 9. US Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 10. US Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Organic Developments Done by Companies
Table 22. Inorganic Developments Done by Companies
Table 23. Glossary of Terms
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Market Segmentation
Figure 2. North America Monoclonal Antibodies (mAbs) Market Overview
Figure 3. Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. North America Monoclonal Antibodies (mAbs) Market, Industry Landscape
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market
Figure 9. North America Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 10. North America Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)
Figure 11. Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 15. North America Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
Figure 16. In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. North America Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
Figure 19. Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. North America Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
Figure 26. Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. North America Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
Figure 30. Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. North America: Monoclonal Antibodies (mAbs) Market, by Key Country – Revenue (2021) (US$ Million)
Figure 34. North America Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
Figure 36. US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Impact of COVID-19 Pandemic in North American Country Markets
Figure 40. Growth Strategies Done by the Companies in the Market, (%)
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America monoclonal antibodies market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.